guest ::
| Home > Publications database > Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. |
| Home > Publications database > Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. |
| Journal Article | DKFZ-2021-00462 |
; ; ; ; ; ; ; ; ; ;
2021
Oxford University Press
Oxford
This record in other databases: 
Please use a persistent id in citations: doi:10.1093/noajnl/vdab002
Abstract: Medulloblastoma (MB) comprises four subtypes of which group 3 MB are the most aggressive. Although overall survival for MB has improved, the outcome of group 3 MB remains dismal. C-MYC (MYC) amplification or MYC overexpression which characterizes group 3 MB is a strong negative prognostic factor and is frequently associated with metastases and relapses. We previously reported that MYC expression alone promotes highly aggressive MB phenotypes, in part via repression of thrombospondin-1 (TSP-1), a potent tumor suppressor.In this study, we examined the potential role of TSP-1 and TSP-1 peptidomimetic ABT-898 in MYC-amplified human MB cell lines and two distinct murine models of MYC-driven group 3 MBs.We found that TSP-1 reconstitution diminished metastases and prolonged survival in orthotopic xenografts and promoted chemo- and radio-sensitivity via AKT signaling. Furthermore, we demonstrate that ABT-898 can recapitulate the effects of TSP-1 expression in MB cells in vitro and specifically induced apoptosis in murine group 3 MB tumor cells.Our data underscore the importance of TSP-1 as a critical tumor suppressor in MB and highlight TSP-1 peptidomimetics as promising novel therapeutics for the most lethal subtype of MB.
Keyword(s): AKT ; MYC ; PI3K ; TSP-1 ; medulloblastoma
; ; 
; 
; ; Article Processing Charges ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DOAJ Seal ; DOAJ Seal ; Emerging Sources Citation Index ; Fees ; Fees ; PubMed Central ; Web of Science Core Collection
|
The record appears in these collections: |
